To evaluate the safety, tolerability and feasibility of a single intravenous (IV) infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other oral DMARDs for at least 6 months and who have had an incomplete response to at least one course of a TNFα inhibitor.

Overall safety will be based on the overall assessment of AE/SAEs, Vital Signs, Physical Examination, clinical laboratory tests, ECGs, pulmonary function tests and Chest x-ray.

Read more: http://www.clinicaltrials.gov/ct2/show/NCT01851070?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30